• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509

Methyl 3-bromo-5-isopropoxybenzoate (CAS No. 1255574-48-1): A Versatile Intermediate in Modern Pharmaceutical Synthesis

Methyl 3-bromo-5-isopropoxybenzoate (CAS No. 1255574-48-1) is a significant intermediate in the field of pharmaceutical synthesis, playing a crucial role in the development of various therapeutic agents. This compound, characterized by its unique structural features, has garnered attention due to its utility in constructing complex molecular frameworks essential for drug design and development.

The molecular structure of Methyl 3-bromo-5-isopropoxybenzoate consists of a benzoate core substituted with a bromine atom at the 3-position and an isopropoxy group at the 5-position. This specific arrangement of functional groups makes it a valuable building block for synthesizing more intricate pharmacophores. The presence of both bromine and isopropoxy groups provides multiple sites for further chemical modification, enabling chemists to tailor the compound for specific biological activities.

In recent years, the demand for novel pharmaceutical compounds has surged, driven by the need for more effective and targeted therapies. Methyl 3-bromo-5-isopropoxybenzoate has emerged as a key intermediate in this landscape, facilitating the synthesis of molecules with potential applications in oncology, immunology, and neurology. Its versatility allows for the creation of derivatives with enhanced binding affinity and selectivity, which are critical factors in drug development.

One of the most compelling aspects of Methyl 3-bromo-5-isopropoxybenzoate is its role in constructing heterocyclic scaffolds. Heterocycles are widely recognized for their prevalence in biologically active compounds, and the ability to incorporate them into drug candidates is highly desirable. The benzoate moiety serves as an excellent platform for such modifications, allowing for the introduction of nitrogen-containing rings that can interact with biological targets in sophisticated ways.

Recent studies have highlighted the importance of Methyl 3-bromo-5-isopropoxybenzoate in the synthesis of kinase inhibitors, which are pivotal in treating various forms of cancer. By serving as a precursor for more complex structures, this compound enables the development of molecules that can selectively inhibit specific kinases involved in tumor growth and progression. The bromine atom at the 3-position is particularly useful for cross-coupling reactions, such as Suzuki-Miyaura couplings, which are commonly employed to introduce aryl groups into pharmacophores.

The isopropoxy group at the 5-position adds another layer of functionality to Methyl 3-bromo-5-isopropoxybenzoate, providing a site for further derivatization. This group can be easily modified through various chemical transformations, including etherification and hydrolysis, allowing for the creation of a diverse array of derivatives with tailored properties. Such modifications are essential for optimizing pharmacokinetic profiles and improving drug-like characteristics.

The pharmaceutical industry has increasingly leveraged computational methods to accelerate the discovery and optimization of new drug candidates. Predictive modeling and virtual screening have become indispensable tools in this process, and intermediates like Methyl 3-bromo-5-isopropoxybenzoate play a critical role in these endeavors. By integrating structural data into computational pipelines, researchers can identify promising lead compounds more efficiently, reducing the time and cost associated with traditional high-throughput screening methods.

In conclusion, Methyl 3-bromo-5-isopropoxybenzoate (CAS No. 1255574-48-1) represents a cornerstone in modern pharmaceutical synthesis. Its unique structural attributes and functional groups make it an indispensable intermediate for constructing complex drug molecules with potential therapeutic applications across multiple disease areas. As research continues to evolve, this compound will undoubtedly remain at the forefront of drug discovery efforts, contributing to advancements that improve patient outcomes worldwide.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)